Daily evidence digest

30 July 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Mood disorders and risk of COVID-19, tofacitinib for COVID-19 pneumonia, identifying and tracking SARS-CoV-2 variants

Peer reviewed journals featured:
- A systematic review on mood disorders and COVID-19 risk [here](#)
- A randomised clinical trial of tofacitinib in hospitalised patients with COVID-19 pneumonia [here](#)
- Observational studies on:
  - COVID-19 breakthrough infections in vaccinated healthcare workers [here](#)
  - Serologic surveillance and phylogenetic analysis of SARS-CoV-2 infection in hospital healthcare workers [here](#)
- Commentary on identifying and tracking SARS-CoV-2 variants [here](#)

Letters and correspondence discussed:
- Effect of targeted behavioural science messages on COVID-19 vaccination registration in healthcare workers [here](#)
- Pfizer-elicted neutralisation against new SARS-CoV-2 spike variants [here](#)
- Bamlanivimab as monotherapy in two immunocompromised COVID-19 patients [here](#)
- Very rare cases of thrombosis with thrombocytopenia after the second dose of AstraZeneca [here](#)

Pre-peer review articles featured:
- Vaccine effectiveness when combining AstraZeneca vaccine as the first dose with an mRNA vaccine as the second dose [here](#)
- Six month safety and efficacy of Pfizer vaccine [here](#)
- COVID-19 vaccine cash and lottery incentives experiment [here](#)

News and blogs:
- How COVID-19 infects cells and why the Delta variant is so dangerous [here](#)
- Evidence used to support mass lateral flow testing in the UK [here](#)
- More US institutes, universities, and businesses make masks mandatory as cases rise sharply [here](#)
- NEJM audio interview on looking back and looking forward in COVID-19 [here](#)
- The Delta variant, and a ‘super’ COVID-19 antibody [here](#)